Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABOSTO:MNTC +9.26%72 Receivables Turnover is 1.11 as of Jun. 2026. GuruFocus rates OSTO:MNTC with a GF Score™ of 72/100 and a GF Value™ of kr26.13 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Mentice AB ranks worse than 75.71% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Mentice AB's Revenue for the
three
months ended in Jun. 2026 was kr79.6 Mil. Mentice AB's average Accounts Receivable for the
three
months ended in Jun. 2026 was kr71.8 Mil.
Hence, Mentice AB's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.11.
Mentice AB (OSTO:MNTC) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Mentice AB Receivables Turnover Related Terms
Mentice AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Mentice AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MNTC vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Mentice AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Mentice AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (OSTO:MNTC) has a Receivables Turnover of 1.11 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Mentice AB and its competitors. According to the industry distribution chart, Mentice AB ranks #614 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 75.7%.
Is Mentice AB's Receivables Turnover too high?
Mentice AB's current Receivables Turnover is 1.11. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Mentice AB's value of 1.11 is 79.9% below this industry median. Based on the distribution chart, Mentice AB ranks #614 out of 811 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Mentice AB has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #614 out of 811 companies for Receivables Turnover. This places Mentice AB in the lower half of its industry. The industry median Receivables Turnover is 5.51. Mentice AB's value of 1.11 is 79.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current Receivables Turnover of 1.11 is 79.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current Receivables Turnover is 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (OSTO:MNTC) is currently considered Possible Value Trap. The stock's GF Value™ is kr26.13, compared to a current price of kr14.75 — trading 43.6% below its estimated fair value. The current Receivables Turnover is 1.11 and 79.9% below the Medical Devices & Instruments industry median of 5.51. Mentice AB's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Mentice AB (OSTO:MNTC), the current Receivables Turnover is 1.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (OSTO:MNTC) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of kr14.75 is trading 43.6% below its estimated GF Value™ of kr26.13.
GuruFocus considers Mentice AB to be Possible Value Trap.
Key valuation signals for OSTO:MNTC:
Receivables Turnover: 1.11
GF Value™: kr26.13 vs. price of kr14.75 (43.6% below fair value)
Industry Position: 79.9% below the Medical Devices & Instruments median (#614 of 811)
No single metric tells the full story. See the OSTO:MNTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
72GF Score
Get the complete analysis for OSTO:MNTC
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MNTC has been successfully added to your 
